Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust.
Professor Justin Stebbing specialises in a range of malignancies, their treatment with immunotherapy (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Professor Stebbing’s original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009.
Professor Stebbing has published over 600 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences. His focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells and cell free DNA. His laboratory work is concentrated on new druggable target discovery and gene regulation examining the role of non-coding RNAs in stem cells. The charity Action Against Cancer www.aacancer.org has been set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.
He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. He chairs the World Vaccine Congress and the Irish Cancer Society oversight committee and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and the Lancet Oncology; he was awarded the Silvia Lawler prize in 2015. Recently, Justin's team published in Nature Medicine the discovery of a new cancer-causing gene which we have now implicated in breast, gastro-intestinal, lung and other solid tumours. The National Institute for Health Research (NIHR) awarded Justin Stebbing its first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. The focus of this is understanding why some patients with cancer relapse, and developing a program to reverse this and prevent it. With the excellent research record we have at Imperial College London and the clinical expertise from Imperial College Healthcare NHS Trust, we believe we are ideally placed to achieve this.
He has an extensive clinical practice and links this to a wide number of translational research studies and immunotherapy trials including recent biosimilar studies. In 2016 Justin was internationally recognised with his appointment as Editor-in-Chief of Oncogene (Springer Nature's foremost cancer journal) and election to the American Society for Clinical Investigation.
Sir Michael Parkinson meets Professor Justin Stebbing
et al., 2017, Phase I clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6, Breast, Vol:32, ISSN:0960-9776, Pages:S68-S69
Stebbing J, Baranau Y, Baryash V, 2017, CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017), Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:E433-E433
et al., 2017, The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer, Molecular Cancer Therapeutics, Vol:16, ISSN:1535-7163, Pages:2246-2256
Harding V, Stebbing J, 2017, Liquorice: a treatment for all sorts?, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:1155-1155
et al., 2018, Role of SMAD proteins in colitis-associated cancer: from known to the unknown, Oncogene, Vol:37, ISSN:0950-9232, Pages:1-7
Craddock C, Cathcart P, Stebbing J, 2017, Quackery Chilli-too hot to handle?, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:1005-1005
et al., 2017, CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:917-928
Cathcart P, Craddock C, Stebbing J, 2017, Quackery Fasting: starving cancer, Lancet Oncology, Vol:18, ISSN:1470-2045, Pages:431-431
et al., 2017, Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma, The Lancet, Vol:389, ISSN:0140-6736, Pages:68-68
et al., 2017, The relationship between ethnicity, social deprivation and late presentation of colorectal cancerle, Cancer Epidemiology, Vol:47, ISSN:1877-7821, Pages:88-93
et al., 2017, Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors, Cell Reports, Vol:18, ISSN:2211-1247, Pages:1687-1698
et al., 2017, Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR, Nucleic Acids Research, Vol:45, ISSN:0305-1048, Pages:4401-4412
Balachandran K, Stebbing J, 2016, Turmeric: a spice for life?, Lancet Oncol, Vol:17
et al., 2017, Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer, Clinical Chemistry, Vol:63, ISSN:0009-9147, Pages:532-541
et al., 2017, The need for multidisciplinarity in specialist training to optimize future patient care, Nature Reviews Clinical Oncology, Vol:14, ISSN:1759-4774, Pages:508-517
et al., 2016, Initiation of adjuvant chemotherapy within 8weeks of elective colorectal resection improves overall survival regardless of reoperation, Colorectal Disease, Vol:18, ISSN:1462-8910, Pages:1041-1049
et al., 2017, Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention, Oncogene, Vol:36, ISSN:0950-9232, Pages:877-884
et al., 2012, A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI), ELSEVIER SCIENCE BV, Pages:1013-1020, ISSN:0168-8278